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STUDY PROTOCOL Open Access
Randomized clinical trial of medial
unicompartmentel versus total knee
arthroplasty for anteromedial tibio-femoral
osteoarthritis. The study-protocol
Jacob Fyhring Mortensen1* , Lasse Enkebølle Rasmussen2, Svend Erik Østgaard3, Andreas Kappel3, Frank Madsen4,
Henrik Morville Schrøder5 and Anders Odgaard6
Abstract
Background: In treatment of isolated medial unicondylar osteoarthritis of the knee, it is possible to choose between
medial unicondylar knee arthroplasty (mUKA), or a total knee prosthesis (TKA). The demand for a blinded multicenter
RCT with the comparison of mUKA and TKA has been increasing in recent years, to determine which prosthesis is
better. Supporters of TKA suggest this treatment gives a more predictable and better result, whereas supporters of UKA
suggest it is unnecessary to remove functional cartilage in other compartments. If the mUKA is worn or loosens,
revision surgery will be relatively easy, whereas revision-surgery after a TKA can be more problematic.
Methods: A double-blinded multicenter Randomized Clinical Trial setup is the aim of the study. 6 hospitals throughout
all 5 municipal regions of Denmark will be participating in the study. 350 patients will be included prospectively.
Follow-up will be with PROM-questionnaires and clinical controls up to 20 years.
Discussion: Results will be assessed in terms of 1) PROM-questionnaires, 2) Clinical assessment of knee condition, 3)
cost analysis. To avoid bias, all participants except the theatre-staff will be blinded.
PROMs: OKS, KOOS, SF36, Forgotten Joint Score, EQ5D, UCLA activity scale, Copenhagen Knee ROM scale, and Anchor
questions. Publications are planned at 2, 5 and 10 years after inclusion of the last patient. The development of variables
over time will be analyzed by calculating the area under the curve (AUC) for the variable relative to the initial value,
and comparisons of the between-group differences will be based on parametric statistics. In this study, we feel that we
have designed a study that will address these concerns with a well-designed double-blinded multicentre RCT.
Trial registration: ClinicalTrials.gov ID: NCT03396640.
Initial Release: 09/19/2017.
Date of enrolment of first participant: 10/11/17.
Keywords: Medial Unicondylar knee arthroplasty, Total knee arthroplasty, OKS, Anteromedial osteoarthritis, Knee
replacement
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Background
The causes of knee joint degenerative disease are multifac-
torial. It is known that trauma (resulting from meniscus,
ligament or cartilage lesions), overload (obesity, malalign-
ment), other disorders (e.g. rheumatoid arthritis) and gen-
etic reasons all play a role in osteoarthritis (OA). Primary
OA is knee degenerative disease with unknown aetiology
[1]. The knee has three compartments, all of which can
suffer from OA and there can thus be seen tri-, bi- or uni-
compartmental OA. The bicompartmental OA can occur
in three combinations, where the combination of medial
and patellofemoral involvement is the most frequent [2]. In
most patients with knee unicompartmental OA, the
arthritis is confined to the medial compartment [3], where
it is most often anteromedial (AMOA).
AMOA can be treated with total knee arthroplasty
(TKA) or medial unicompartmental knee arthroplasty
(UKA) (Fig.1). In Denmark, the proportion of UKA has
increased during the period 2013–2015 from 11% (2699/
24574), to 16,8% (1344/7980) in 2016 [4]. The proportion
may be expected to increase to above 30% in line with the
proportion in the hospitals that are the most frequent users,
if the general perception of the outcome remains positive.
Despite the increasing usage, UKA is still controversial. Ac-
cording to a recent comparative meta-analysis of 374,934
arthroplasties, revisions of mUKA occur at an annual rate
of 2.18-fold that of TKA [5]. In a survival analysis of a
high-volume centre, the 9-year survival rate was 93% [6].
TKA-followers believe that the isolated AMOA is best
treated with total knee arthroplasty (TKA) which is con-
sidered the gold standard, while UKA-followers believe
that the TKA is an unnecessarily large intervention as it
is more invasive and removes potentially good cartilage.
UKA preserves bone and cartilage which makes revision
surgery easier if necessary [7–10]. “In addition, mUKA
has fewer complications, requires less rehabilitation, and
may provide a better range of motion and superior func-
tion compared with total knee arthroplasty. Because it is
associated with a higher risk of revision compared with
that of total knee arthroplasty, unicompartmental knee
arthroplasty remains a controversial procedure” [10]. A
large register study from England and Wales [11] found
that UKAs had worse implant survival than TKA, but less
complications. They found worse UKA survival with revi-
sion (sub hazard ratio 2.12) and revision/reoperation
(1.38) than TKAs at 8 years. In the same study, mortality
was found significantly higher for TKA at all time points
than for UKA (30 day: 0,23; 8 year: 0,85). Length of stay,
complications, and rate of readmission were all higher for
TKA than UKA [11].
When comparing UKA and TKA, findings are open to
bias, especially comparisons of revision rates from national
registries [12]. Murray et al. explain this as a selection bias
due to UKAs tending to be implanted in younger, fitter and
more active patients than TKA, while younger, fitter and
more active patients tend to have higher revisions rates.
Also they explain a measurement bias, as the decision to
revise is influenced by the type of arthroplasty. Since UKA
is generally easier to revise than TKA, and the outcomes of
revision are considered to be better, the threshold for
revision of UKA is lower than for TKA [12].
Over the coming years an increase in the number of
knee replacements is expected [13]. Effective treatment
with good clinical outcomes assessed in relation to the
treatment costs will be an ever-increasing requirement
for cost-effectiveness and maximizing usage of resources.
There are no comparative studies on the cost and
economic effectiveness between mUKA and TKA. While
there are register studies without adequate scientific
evidence, some still believe that register studies should
rule the ultimate decision in the quality of implant types
and brands, as well as their continued usage [14–16].
Data from register studies is being used more and more
in the supply and sales processes. Some believe that the
use of UKA implants should be reduced or stopped as a
consequence of their poor performance in registry stud-
ies [16], yet some surgeons prefer the use of mUKA
when possible, which is reflected in the increased rate of
mUKA operations [4]. Murray et al. believe that these
registries usually are biased against the UKA because of
the way they are setup, which leads to selection-, report-
ing-, and measurement-bias [12, 17].
Limited evidence is available to clarify whether AMOA
should be treated with a UKA or TKA. The aim of this
study in a double-blinded randomized multicentre de-
sign is to compare the outcome of UKA and TKA for
AMOA. Studies are currently on-going in the United
Kingdom (TOPKAT) [3], Finland [18], and Sweden [19]
to compare the two prosthesis. As suggested in the
peer-review commentary on Kulshrestha et al., We await
Fig. 1 Pros and Cons of each Knee-replacement
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the results of a large multicentre randomized trial to
provide information on whether specific patient popula-
tions can derive greater benefit from UKA’ [20]. Murray
et al. also conclude that: ‘For a fair comparison of UKA
and TKA, data from randomized controlled trials are re-
quired, and multiple outcome measures should be used
which could include adverse events, patient reported
outcome measures and cost-effectiveness’ [12].
In this study, we feel that we have designed a study
that will address these concerns with a well-designed
double-blinded multicentre RCT.
Methods
The study has been designed as a superiority type,
prospective, double-blinded, parallel-group, multicentre
randomized clinical trial (RCT). Each participant is by lot
[1:1] randomized to either UKA or TKA for the treatment
of AMOA. This trial will comply with the CONSORT
2010 Statement [21] and the SPIRIT guidelines [22] and a
Statistical Analysis Plan (SAP) [23] will be included.
Participants
350 participants will be included consecutively in the
study, from 6 participating hospitals covering all 5 regions
nationally. Participating hospitals include Gentofte,
Næstved, Vejle, Århus, Farsø and Frederikshavn hospitals.
Inclusion/exclusion criteria are listed in Table 1.
Flow
Patients with isolated AMOA, who are referred to one of
the participating departments, will be screened for eligibil-
ity by a knee-surgeon and will be offered inclusion in the
study (see Table 1 and Fig. 2). The patient will then receive
verbal and written information regarding the study, and
will consider participation, after signing the consent form,
which is given to the surgeon. Within 3 days the patient
will be contacted by one of the investigators ensuring that
the patient has read and understood all the received
information, and they will be given the opportunity to ask
questions. If they consent, prior to surgery they must
answer baseline questionnaires and have baseline a
surgical clinical evaluation. Pre- and postoperative
follow-up is carried out according to Table 2.
Intervention
Based on the randomization, the patient will have either:
1) Cementless medial Oxford partial knee, phase 3-alpha,
or 2) Cemented TKA.
The TKA brand and model will be the individual
surgeon’s preferred TKA. General anaesthesia or spinal
analgesia will be used depending on the surgeon and
anaesthetist preferences. The usage of a drain is also at the
discretion of the surgeon. Local infiltration analgesics will
be used. All patients will undergo surgery using a midline
skin incision, and the length of UKA incisions will be as a
TKA incision to ensure blinding postoperatively. After the
skin incision, the joint-capsule will then be.
incised according to the standard operation technique
of either prosthesis. All pre-, per-, and post-operative re-
gimes of each department will be followed besides the
regime described above. Surgeons from 7 centers with
long experience of UKA will participate. The individual
surgeon should have a personal proportion of at least
20% medial UKA of primary procedures for at least
three months before study participation to have a
homogenous group of surgeons in the trial, and to
minimize the risk of revision [6].
Primary outcome measure
Oxford Knee Score (OKS) is the primary outcome
measure. OKS is a patient reported outcome measure
(PROM) questionnaire with a scale range from 0 (severe
arthritis) – 48 (satisfactory joint function) [24]. OKS
consists of 12 simple questions and is easy to fill out for the
patient. There are a low number of incorrectly completed
forms [24, 25], and the form can be answered in a short
time. OKS has been shown to be sensitive and OKS
has been translated to and validated in multiple
languages [26, 27].
Secondary outcome measures
Patient reported outcome measures.
Table 1 Inclusion and Exclusion Criteria
Inclusion Criteria Exclusion Criteria:
Non-knee specific
Exclusion Criteria:
Knee-specific
- AMOA severe enough to justify arthroplasty
- Diagnosis ensured by standard x-ray with PA,
lateral, and skyline
- Bone-on-Bone medially
- Lack of effect of conservative treatment
- Non-danish citizenship
- Insuff. Danish capability
- Under 18 years
- Dementia
- Severe Psych. Disorder
- Alcohol og drug abuse
- Disseminated malignancy
- Severe systemic disease
- Rheumatoid Arthritis
- Employed at one of the participating
departments
- Sagittal/coronal instability
- Lateral and/or patellofemoral OA
- Complex regional pain syndrome
- Arthrofibrosis
- Extension defect < 10
- Fleksion < 110
- Lateral subluxation or bone-on-bone visualized
on skyline.
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A compiled questionnaire containing a number of gen-
eric and disease-specific PROMs will be sent to participants
to be answered pre-operatively and post-operatively at 1–
2–3-6-9-12-18months and at 2–3–4-5-6-8-10-12-14-16-
18-20 years (see Table 2).
SF36
Evaluating individual patients’ generic health status This
PROM has the potential to allow assessments of cost-effect-
iveness, and monitoring/comparing disease burden [28].
EQ5D + EQ5D vas
Standardized instrument for measuring generic health status,
without and with a visual analogue scale, respectively [29].
Forgotten joint score
The patients ability to forget about a joint as a result of
successful treatment [30, 31].
KOOS
The score is based on the patient’s own assessment and
is an extension of WOMAC, which can also be calcu-
lated from the completed form [32, 33].
UCLA activity scale
Assessment of patient activity outcome evaluations of
lower extremity joint reconstructions [34, 35].
Copenhagen knee ROM scale
Patient reported knee range of motion, picture based [36].
The Oxford Knee Score, KOOS and SF36 for quantifica-
tion of knee function, lower extremity function, and
psychosocial status. In addition to being well documented,
the patient-reported outcome measures (PROMs) are based
on self-assessment, allowing completion of forms by mail/
email, which is a great advantage. WOMAC will be calcu-
lated from the KOOS. The Forgotten Joint Score is also
relevant to use, as the patient-awareness of the artificial
knee-joint or lack thereof, correlates to the success of the
treatment. Some could argue that there could be a ‘ceiling
effect’ using PROMs, but as seen with previous experience,
almost no patients score maximum of points [37].
Knee score of KSS is not considered as relevant in spe-
cific measurements, and as an example, ROM in the clin-
ical follow-ups will be of greater value. Unfortunately,
OKS is not entirely specific, since it has been found that
major hip or spine disease can affect the score [25]. How-
ever, all patients will be randomized, and confounders
Fig. 2 Consort Flow Diagram
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should be equally distributed between the two groups.
HSS score and KSS have been shown to be influenced by
demographic characteristics [38], and this may also be the
case for OKS, KOOS and SF-36. This motivates the re-
cording of the level of education and co-morbidity, such
that randomization may be checked for this.
Clinical outcome measures
Physical examinations will be performed at baseline and
post-operatively at 2 weeks, 4 months, and 1, 2, 10 and
20 years. If a clinical control after 2 weeks cannot be per-
formed, a telephone call will be performed instead.
Knee ROM
The number of degrees an examiner is able to move the
knee joint through its full range of motion with no active
effort from the patient (passive movement). Mobility is
measured in degrees using a standard (30 cm) goniometer.
Knee effusion
Measured bilaterally as the circumference with the meas-
uring band placed 1 cm above the base of the patella [39].
Implant survival
Whether the patient has undergone revision surgery of
the arthroplasty or other additional surgery to the knee.
The information will be retrieved for the National Patient
Register (NPR) and from the Danish Knee Register (DKR).
Complications
Fracture, infection, loosening, radiographic radiolucent
line, thromboembolism, other.
Cost utility analysis
The hospital’s accounting department and product sup-
pliers will provide unit costs, which will be combined
with data from the Patient administrative system (PAS),
data from the regional health insurance registry, and
data from Statistics Denmark [40]. Over several years
fees collected will be adjusted for inflation and presented
in prices for the most recently observed year.
QALYs measured with EQ5D will provide endpoints of
the CEA. Quality of life (QOL) will be calculated using the
official Danish time trade off (TTO) from the baseline and
with each follow up [41]. QALY is based on observed
values QOL and calculated for a whole year by estimating
the area under the curve (AUC) with the Trapezoidal rule.
Scored by methods described above, secondary end-
points are SF36 and OKS.
Estimation of univariate and multivariate cost differ-
ence will be calculated between the two treatments.
Due to an expectation of a non-normal distribution of
cost and effect data, primary univariate analysis carried
out will be as a non-parametric bootstrap with arithmetic
mean values based on 2000 bootstrap samples [42]. A sim-
ple T-test will be the secondary univariate analysis [43].
Means of generalized linear method (GLM) that allow
investigating the cost without requirements for data dis-
tribution will be used for the multivariate analysis of
costs. Following covariates are included in the model:
age, gender, diagnosis, preoperative costs, economically
active/not, and pre-operative QOL.
Means of linear regression (OLS) will be used for
multivariate analyses of the impact, with bootstrap sam-
pling of 2000 samples. Following covariates in the model
will be included: age, gender, diagnosis, economically
active/not, and pre-operative QOL [42].
Cox regression will be used additionally at long-term
follow-up.
Missing data in any analysis will only be replaced after
current conventions for used measuring tools, using
multiple imputations. Therefore all analysis can be car-
ried out on complete sets. The estimated net benefit
(NMB) uses the following formula: NMB = RT △E - △C.
RT will be the threshold ratio and will be set for
50,000 US dollars. If the NMB is > 0, the treatment is
cost-effective. Data will be presented with figures of
Table 2 W=weeks, M =months, Y = years, PROM = Patient
Reported Outcome Measures, P/E = Physical examination, Comp
= complications, # = Unblinding of patient treatment
Enrolment Allocation PROM P/E X-ray
Eligibility screening ●
Informed consent ●
Baseline variables ● ● ●
Operation ●
2w ● ●
1 m ●
2 m ●
3 m ●
4 m ●
6 m ●
9 m ●
1y # ● ● ●
18 m ●
2y ● ● ●
3y + 4y ●
5y ●
6y + 8y ●
10y ● ● ●
12y + 14y + 16y + 18y ●
20y ● ● ●
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uncertainty about ICER, along with bootstrap samples of
2000, with paired observations of cost- and power differ-
ence on the cost-effectiveness axis.
On the y-axis, cost data will be allocated. On the
x-axis, effect data. The four quadrants describe the rela-
tionship between the two investigated treatments.
In the northeast quadrant the UKA is more expensive,
but superior. In the southeast quadrant, the UKA will dom-
inate the TKA. In the southwest quadrant UKA is cheaper
but poorer than TKA. In the northwest quadrant, the TKA
is dominant, meaning the UKA is both more expensive and
poorer. The probability of the UKA method will be
described by data with an acceptability curve. A net benefit
figure showing the result of the NMB analysis at different
values of W (willingness to pay) will also be shown.
Sample size
Based on previous studies [37], the difference between
pre- and postoperative OKS has a standard deviation
around 8.4. The minimally clinically important differ-
ence for OKS is 3. Setting the significance level (alpha)
at 5% and the power (1-beta) at 90%, 170 patients are
needed in each group resulting in a total study popula-
tion of 340 patients. This number has been rounded up
to 350 by the research-group.
Randomization
Stratified, permuted block randomization with a 1:1 allo-
cation ratio. Block sizes will be 4, 6, 8 and 10. Stratifica-
tion will be two-dimensional, where hospital is one
dimension and patient sex the other. The randomization
will be done as shortly before surgery as possible.
The random allocation sequence is made digitally by
the coordinating investigator, using a unique database
www.procordo.dk.
Enrolment of participants occurs in the outpatient
clinics of the participating orthopaedic departments,
where all knee surgeons screen patients’ inclusion/exclu-
sion criteria and offer them inclusion in the trial as
appropriate. Prior to surgery the participant will be ran-
domized on-line by the surgeon. The staff will be ad-
vised immediately after randomization, which procedure
will be performed. If the participant is allocated to. the
UKA group and during surgery shows to have wide-
spread arthritis in the knee, the patient will receive a
TKA, but will remain in the study and remain blinded
for 1 year. Hence, analyses will be according to
intention-to-treat principles.
Blinding
Randomization is blinded to everyone (patient, staff,
GP, physiotherapists etc.) except theatre staff, during
the first year following surgery. Blinding is secured by
making a midline skin incision of the knee, regardless
of randomization. If a UKA is performed, the skin is
pulled medially, and the joint capsule is incised
medially as the standard operation manual dictates
(Fig. 3). After surgery, the patient will have numerous
contacts with different types of medical staff. All
medical staff involved is thoroughly instructed in the
principles of blinding, and are themselves blinded to
the operation notes, radiographs and discharge sum-
maries. Post-operative control x-ray will be done at
the 2-week clinical follow-up, or shortly before dis-
charge. The radiographic wards are strictly instructed
not to reveal the x-ray result to the participant. In
case of accidental unblinding of staff, they are
instructed not to share the information with the par-
ticipant. Participants are asked at all contacts whether
their randomization has been revealed, and if so, how.
Statistical analysis plan
Changes between pre- and postoperative status will be
treated with paired statistics, either parametric or non-
parametric depending on the nature of the data. The de-
velopment of variables over time, e.g. Oxford Knee
Score, will be analysed by calculating the area under the
curve (AUC) for the variable relative to the initial value,
and comparisons of the between-group differences will
be based on parametric statistics.
Fig. 3 Midline incision of knee, with medial capsulotomy for mUKA
Mortensen et al. BMC Musculoskeletal Disorders          (2019) 20:119 Page 6 of 8
Statistical comparison of proportions in the two treat-
ment groups will be conducted with chi-squared –test or
Fisher’s exact test. The method is used each time a defined
serious adverse event (SAE) is recorded. Complications, in
contrast to SAE, are divided into knee- and non-knee re-
lated groups. Knee related complications include revision,
re-operation, loosening, deep infection, superficial infec-
tion, unexplained pain, pain, and lack of improvement in
OKS after 6months compared to pre-operatively.
Non-knee related complications include DVT with follow-
ing thromboembolism, anaesthesiology complication, and
death. Out of these complications, the study group
defined Death, Infection, and lack of improvement in OKS
at 6months compared to pre-operatively as an SAE.
All analyses will be based on an ‘Intention-to-treat’
basis. Statistical significance will be judged with 95%
confidence intervals presented.
Analyses are planned early at 2 years after the last par-
ticipant is included, medium at 5 years, and late at 10
years follow-up of last participant.
Interim analysis
The Institutional review board required that a Data Re-
view Board be set in places, which are neutral to the study.
Running, the Board will be informed about any SAE and
the board will be gathered after inclusion of 33 and 66% of
the patients. A possible difference between the groups will
be tested for statistical significance by contingency analysis
(2 × 2 table, chi square test) where p < 0,025 will be
regarded significant. The reason for choosing this low
p-value is that this study group regard this study to be of
high priority, and to protect patients in the future, that
this study only be closed down when an absolute differ-
ence between the interventions can be shown.
Also, at each event of SAE, previous cases of SAE’s will
be analysed, and it will be determined whether one of
the groups has a significant excess risk of complications,
as written above. If it has, the trial will be stopped, and
the results published.
Timeline and ethics
Recruitment of patients started September 2017. Based
on a patient acceptance ratio of 50% and the current
number of partial knees performed in the participating
centres, inclusion is expected to last between one and
two years as a conservative estimate.
The trial protocol has been approved by the Regional
Ethics Committee of the Capital Region of Denmark. It
has been amended once, latest on the 18/03/2018.
Discussion
The investigating group has designed this RCT to ad-
dress international debates whether Oxford medial UKA
is better than TKA for the treatment of AMOA, as
predictions of future demands and usage of medial UKA
are expected to increase. Other similar studies are
on-going, but unfortunately they are lacking in a
study-design that will properly determine superiority of
these two interventions. The TOPKAT-study in the UK
[3] was an unblinded study, which unfortunately will re-
sult in too much bias and uneven spreading of con-
founders. The Finnish FUNCTION-trial [18], is well
designed, but this study group has the opinion that a
sample-size group of 140 patients is too low, and will
not have sufficient power in their study, same as the
Swedish trial [19] with only 80 patients, although their
primary outcome is on muscle mass change results.
The outcome of this trial will provide high-level evi-
dence as to whether a TKA or UKA is beneficial in both
the long and the short term. As the trial will be
double-blinded and performed as a multi-centre study,
potential biases are reduced. Results with primary focus:
1) patient-reported outcomes, 2) clinical results includ-
ing prosthetic survival, and 3) costs.
If the trial results in a high drop-out, a drop-out ana-
lysis will be performed.
Results will be submitted to peer-reviewed inter-
national journals for publication in accordance with the
CONSORT guidelines for reporting of clinical trials.
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